Clinical trial · Observational
Registry Study of Thoracic Reirradiation for Non-Small Cell Lung Cancer (NSCLC) Utilizing Proton Beam Therapy or Intensity Modulated Radiation Therapy
NCT01808677CI-TRIAL-00023623completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this research study is to learn more about the safety of treating NSCLC with reirradiation using standard methods and to look for ways to lessen side effects and improve therapy. Reirradiation is when radiation is given to an area of the body that has previously received a full dose of radiation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Thoracic Reirradiation Registry | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Thoracic Reirradiation Registry
- description
- Data collection on patients being treated with thoracic reirradiation with PBT or IMRT for NSCLC, with or without chemotherapy.
- interventionNames
- Other: Thoracic Reirradiation Registry
Primary outcomes (1)
- measure
- Prevalence of High-Grade Toxicity
- timeFrame
- 5 years
- description
- Primary objective to assess the prevalence of high-grade toxicity in patients being treated with thoracic reirradiation with proton beam therapy (PBT) or intensity modulated radiation therapy (IMRT) for non-small cell lung cancer (NSCLC), with or without chemotherapy. High-grade toxicity defined as CTCAE v4.0 Grade 3 or higher toxicity, or CTCAE v4.0 grade 4 or higher toxicity of the esophagus. Data collected from 1/2/2012 to 1/31/2017. High-grade toxicity rate and its corresponding 95% confidence interval provided at end of study. Logistic regression model used to assess the association between prognostic factors such as total dose to normal tissue structures, time since initial course of RT, failure in same lobe of the lung, failure in nodal regions, and central vs. peripheral location and high-grade toxicity.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. History of previous histologically or cytologically documented NSCLC, stage I-IV. 2. Prior course of radiation therapy or concurrent chemoradiation at least 1 month prior to the current course of radiation therapy. 3. Patients eligible to receive a second course of radiation therapy to the thorax, at the discretion of the treating physician. 4. Patients receiving concurrent chemotherapy or targeted agents will be eligible for this protocol. 3.2 Exclusion Criteria: 1. Life expectancy\<3 months 2. Pregnancy.
References
Publications (0)
Data not yet available
No reference posted for this study.